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S228 Oral Presentationsfrom 48 states. Autologous and allogeneic HCT recipients were
equally likely to enroll (P 5 .59) and view pages (P 5 .74). Across
all races, non-white survivors were less likely to enroll compared
to whites (P\.001), but once enrolled viewed as many pages (P 5
.18). 14% were computer use beginners, 52% were intermediate
users, and 34% were experts; these groups did not differ in pages
viewed (P 5 .89). Survivors from rural versus urban areas were
equally likely to participate (P 5 .45) and utilize the site (P 5 .14).
Once randomized to site access, 70% logged on at least once. The
median number of pages visited was 7 (range 0-179). Participants
$40 years old were more likely to login at least once compared
with those\40 (P 5 .004) but age groups did not differ in pages
viewed (P5 .15). Females weremore likely to visit the site thanmales
(77% vs. 65%, P5 .007) as well as to viewmore pages (M5 21.3, SD
5 28.0 vs. M5 11.7, SD5 18.3, P\.001). Similarly, transplant sur-
vivors\10 years were more likely to enroll in the study than $10
year survivors (P\.001) but did not view more pages (P 5 .26).
Discussion: The internet provides access to long-term HCT survi-
vors.While online approaches reach a broad population and are well
utilized, additional strategies are needed for males and younger than
40 years old HCT survivors to engage them in the online resources.
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In 2009, mutations in the gene for dedicator of cytokinesis 8
(DOCK8) have been identified as the cause of the autosomal recessive
variant of Hyper-IgE syndrome. The clinical presentation of this
primary combined immunodeficiency is characterized by eczema, de-
bilitating viral infections of the skin, chronicmucocutaneous candidi-
asis, pulmonary infections, severe allergies, vascular complications
and a high risk for malignancy, mostly lymphoma or skin cancer.
While the long-term prognosis of affected patients is not yet
clearly defined, the high morbidity and mortality of this disease sug-
gest HSCT as a potential curative measure. On behalf of the EBMT
inborn errors working party we retrospectively studied the outcome
of HSCT in patients with DOCK8 mutations.
A total of fifteen patients from 10 institutions were identified, 4 of
whom had been previously reported. Three patients had malignant
disease. At a median age of 13 years (3-18) transplantation from
aMUD (n5 9), MFD (n5 2) or MSD (n5 4) was carried out. Con-
ditioning was fully myeloablative in 4, of reduced intensity in 10 or
minimal in 1. After amedian follow-up of 8months (2-89) the overall
survival is 80% (12/15). Only one patient had grade III or greater
acute GVHD; he later developed extensive chronic GVHD and
died from infection. Two other patients died, one from sepsis, the
other from progression of pre-existing lymphoma. T-cell chimerism
at last follow-up was.99% in 12/14 and 50-90% in 2/14. Of the 12
surviving patients 9 of 9 who were evaluable had complete correction
of their immunodeficiency. Other symptoms such as eczema (disap-
peared in 11/12, improved in 1/12), allergies (5/7; 2/7), mollusca (6/
8; 2/8), bacterial infections (6/6; 0/6), fungal infections (7/7; 0/7) and
pulmonary function deficits (4/4; 0/4) responded very well. One pa-
tient developed a thyroid carcinoma 7 years post transplant, likely
because of a TBI-containing conditioning regimen.Longer follow-up will be needed to ascertain that HSCT will
correct themalignancy risk, as theDOCK8molecule has been impli-
cated as a tumor suppressor and is expressed in extra-hematopoietic
tissues. A survey to define the natural course of disease and to guide
treatment recommendations for all patients is currently underway on
behalf of ESID and EBMT. In summary, HSCT corrects the immu-
nodeficiency and other disease manifestations in DOCK8 deficiency
and this treatment should be offered at least to all patients with
severe disease manifestations.
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Infantile malignant osteopetrosis (IMO) is due to a heterogeneous
group of mutations resulting in abnormal osteoclast function; more
than half of the IMO cases have mutations in the TCIRG1 gene. Al-
logeneic hematopoietic cell transplantation (HCT) is currently the
only curative therapy for IMO. We report here our experience in
IMO at King Faisal Specialist Hospital & Research Center
(KFSHRC).
Patients andMethods: Between January 1993 andDecember 2008,
25 children with IMO underwent HCT at KFSHRC, median time
from diagnosis to HCT was 3.7 month (range, 1-66 months), and
median age atHCTwas 6months, (range, 2-75months), ten patients
(40%) had severe hematopoietic deficiency, and severe visual impair-
ment at HCT. Donor source was fully matched siblings in 23 pa-
tients and partially matched unrelated cord blood in 2 patients. All
patients were conditioned with busulfan (BU) and cyclophospha-
mide (CY).
Results:Nine mutations were detected in TCIRG1, seven of which
were novel. One novel mutation was detected in CLCN7 gene.
Seven patients had no mutation detected in TCIRG1, CLCN7 or
OSTM genes. Engraftment occurred in 23 patients (92 %). Acute
GVHD and veno-occlusive disease occurred in 6 and 4 patients, re-
spectively. Seven patients (28%) had secondary graft failure at a me-
dian of 6 months post HCT (range, 3-14 months). Sixteen (64%)
patients remain alive. Chimerism studies at the last contact are avail-
able for 14 patients, and all but 2 patients have stable mixed chime-
rism. At median follow-up of 9.8 years (95% CI: 5.4-14.2 years)
ranging from 3.6 to 15.2 years, the overall survival (OS) and event-
free survival (EFS) are 55%, and 52%, respectively. All surviving pa-
tients had evidence of osteoclast function at the last evaluation, and
none of them had any further vision deterioration.
Conclusion: Children with IMO have favorable survival after allo-
geneic HCT. Although engraftment is probably not significantly af-
fected by the age, we recommend that early HCT be done to
preserve vision and final height as much as possible. Due to the small
number of patients, and the fact that a good percentage of our cases
had no mutations in the known genes, we were not able to relate
a specific genotype with outcome. However, TCIRG1 appears to
be an important gene in IMO in Saudi patients, similar to other pop-
ulations. Larger series are required to demonstrate a genotype–phe-
notype, and genotype-outcome correlation.
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Background: Invasive fungal infections are of great concern in pedi-
atric HSCT recipients. Voriconazole is an important drug both for
prophylaxis as well as for therapy. Optimum trough levels are be-
tween 1-5 mg/l. It is unclear whether these levels are reached with
current pediatric dosing schedules. We retrospectively analysed
the use of voriconazole in our unit between 2007 and 2011.
Use of voriconazole: 92 children between 0-19 years of age under-
went HSCT. 57 of them (64%) were treated with voriconazole. 21%
of them were\2 yrs, 47% 2-12-yrs and 32 % .12 yrs.
